Context Therapeutics Inc.
CNTXNASDAQHealthcare● Active
$1.71
$-0.04(-2.29%)
Market Cap$157113393
P/E Ratio—
52W High$3.62
52W Low$0.56
Context Therapeutics Inc. (CNTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CNTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.09
Est. -$0.12 · +25.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CNTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.08 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.12 | -$0.09 | +25.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.11 | -$0.14 | -27.3% | — | $-0.00B | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.09 | -$0.10 | -11.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.06 | -$0.09 | -50.0% | — | — | — |
| — Q2 FY2025 | May 7, 2025 | -$0.05 | -$0.05 | +0.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.05 | -$0.04 | +20.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.11 | -$0.22 | -100.0% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.09
EPS Est.
-$0.12
EPS Surpr.
+25.0%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.14
EPS Est.
-$0.11
EPS Surpr.
-27.3%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-11.1%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.06
EPS Surpr.
-50.0%
Revenue
—
Q2 FY2025
May 7, 2025
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.05
EPS Surpr.
+20.0%
Revenue
—
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.22
EPS Est.
-$0.11
EPS Surpr.
-100.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.20 | $-0.20 | $-0.20 | 3 |
| Q3 FY2028 | $-0.20 | $-0.20 | $-0.20 | 3 |
| Q2 FY2028 | $-0.19 | $-0.19 | $-0.19 | 3 |
| Q1 FY2028 | $-0.19 | $-0.19 | $-0.19 | 3 |
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 2 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +25.0% | $2.44 | $2.41 | -1.23% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -27.3% | $2.92 | $2.99 | +2.40% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -11.1% | $1.11 | $1.13 | +1.80% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -50.0% | $0.70 | $0.70 | -0.14% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $0.81 | $0.77 | -4.28% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +20.0% | $0.82 | $0.77 | -5.98% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -100.0% | $2.21 | $2.22 | +0.45% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +50.0% | $2.31 | $2.34 | +1.30% |
Q2 FY2026-1.23%
Report Date
May 6, 2026
EPS Beat/Miss
+25.0%
Price Before
$2.44
Price After
$2.41
Q1 FY2026+2.40%
Report Date
Mar 19, 2026
EPS Beat/Miss
-27.3%
Price Before
$2.92
Price After
$2.99
Q4 FY2025+1.80%
Report Date
Nov 5, 2025
EPS Beat/Miss
-11.1%
Price Before
$1.11
Price After
$1.13
Q3 FY2025-0.14%
Report Date
Aug 6, 2025
EPS Beat/Miss
-50.0%
Price Before
$0.70
Price After
$0.70
Q2 FY2025-4.28%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.81
Price After
$0.77
Q1 FY2025-5.98%
Report Date
Mar 20, 2025
EPS Beat/Miss
+20.0%
Price Before
$0.82
Price After
$0.77
Q4 FY2024+0.45%
Report Date
Nov 6, 2024
EPS Beat/Miss
-100.0%
Price Before
$2.21
Price After
$2.22
Q3 FY2024+1.30%
Report Date
Aug 7, 2024
EPS Beat/Miss
+50.0%
Price Before
$2.31
Price After
$2.34
Avg Beat Reaction-2.55%
Avg Miss Reaction+1.13%
Beat Rate4 / 8 quarters
Largest Move-5.98% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CNTX ends December
Context Therapeutics Inc. (CNTX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.09 — beating the analyst consensus of $-0.12 by +25.0%. The next CNTX earnings date is expected around September 1, 2026.
Each quarter, investors track CNTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CNTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CNTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CNTX earnings · 5 questionsContext Therapeutics Inc.'s next earnings report is expected around September 1, 2026. CNTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CNTX historically reports after market close (AMC).
CNTX earnings datewhen is CNTX earningsCNTX next earnings datewhen does CNTX report earningsCNTX earnings calendar
▸ Source: FMP · Context Therapeutics Inc. SEC filings · US GAAP · Context Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026